| 股票名称 | 沽空金额↓ | 沽空比率 | 偏离值 | | --- | --- | --- | --- | | 阿里巴巴-W(09988) | 15.03 亿元 | 10.51% | -2.02% | | 中国平安(02318) | 13.20 亿元 | 32.00% | 3.87% | | 腾讯控股(00700) | 8.92 亿元 | 6.75% | -1.56% | | 汇丰控股(00005) | 7.71 亿元 | 17.54% | -1.77% | | 美团-W(03690) | 7.60 亿元 | 23.38% | 1.92% | | 小米集团-W(01810) | 6.98 亿元 | 16.03% | -5.75% | | 新鸿基地产(00016) | 5.85 亿元 | 45.19% | 6.30% | | 紫金矿业(02899) | 5.73 亿元 | 23.75% | 4.90% | | 宁德时代(03750) | 5.49 亿元 | 27.70% | 3.43% | | 友邦保险(01299) | 5.41 亿元 | 24.00% | 5.57% | 前十大沽空偏离值排行 | 股票名 ...

格隆汇2月26日丨加科思-B(01167.HK)公布，定于2026年3月10日(星期二)举行董事会会议，以审议及批 准(其中包括)公司及其附属公司截至2025年12月31日止年度之全年业绩及其发布，以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 董事長 王印祥 香港，2026年2月26日 於本公告日期，董事會成員包括董事長兼執行董事王印祥博士；執行董事王曉潔女士及 胡雲雁女士；非執行董事陳德禮博士；及獨立非執行董事宋瑞霖博士、魯白博士及吳革 博士。 董事會召開日期 加科思藥業集團有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2026年3月10日（星 期二）舉行董事會會議，以審議及批准（其中包括）本公司及其附屬公司截至2025年12月31 日止年度之全年業績及其發佈，以及處理其他事項。 承董事會命 加科思藥業集團有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） ...

iADC：以STING 激动剂为payload，布局肿瘤免疫2.0。下一代ADC 平台"iADC"创新性地以ADC 形式通 过抗体介导的特异性识别，将STING 激动剂精准输送至肿瘤细胞，避免全身暴露，将冷肿瘤转化成热 肿瘤治疗PD-1 抗体无效的患者。平台首个临床候选药物HER2-STING iADC（JAB-BX467）前已确定 PCC，公司计划于2026H2 提交IND。此外，通过将专有STING 激动剂与不同的TAA 靶向抗体共轭，公 司正在开发一系列iADC 项目。iADC 平台经概念验证后，以STING 激动剂作为载荷的新型ADC 有望应 对ICI 疗法低反应率及传统ADC 毒性层面的双重挑战。 tADC：以KRAS 抑制剂为payload，开辟靶向治疗新范式。公司将高效KRASG12D 小分子抑制剂JAB- 22000 与抗体偶联，创新性构建KRAS G12D tADC平台。平台首个临床候选药物EGFR G12Di tADC （JAB-BX600）目前已确定PCC，公司计划于2026H2 提交IND。此外，研发管线中有多个未公开的 ADC候选药物正在积极推进中。tADC 平台经概念验证后，具备显 ...

证 券 研 究 报 告 加科思-B（01167.HK）深度研究报告 强推（首次） pan-KRAS 抑制剂价值重估空间大 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 156 | 234 | 627 | 508 | | 同比增速(%) | 145.1% | 50.5% | 167.6% | -19.1% | | 归母净利润(百万元) | -156 | -15 | 313 | 192 | | 同比增速(%) | 56.6% | 90.7% | 2,258.6% | -38.6% | | 每股盈利(元) | -0.20 | -0.02 | 0.40 | 0.24 | | 市盈率(倍) | -29 | -308 | 14 | 23 | | 市净率(倍) | 4.8 | 4.9 | 3.7 | 3.2 | 资料来源：公司公告，华创证券预测 注：股价为 2026 年 2 月 23 日收盘价 港股公司 生物医药Ⅲ 2026 年 02 ...

证 券 研 究 报 告 资料来源：公司公告，华创证券预测 注：股价为 2026 年 2 月 23 日收盘价 港股公司 生物医药Ⅲ 2026 年 02 月 24 日 目标价：11.26 港元 当前价：6.37 港元 华创证券研究所 证券分析师：刘浩 邮箱：liuhao@hcyjs.com 执业编号：S0360520120002 加科思-B（01167.HK）深度研究报告 强推（首次） pan-KRAS 抑制剂价值重估空间大 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 156 | 234 | 627 | 508 | | 同比增速(%) | 145.1% | 50.5% | 167.6% | -19.1% | | 归母净利润(百万元) | -156 | -15 | 313 | 192 | | 同比增速(%) | 56.6% | 90.7% | 2,258.6% | -38.6% | | 每股盈利(元) | -0.20 | - ...

Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

Group 1 - The stock of JACOS-B (01167) rose over 6%, currently at 6.06 HKD with a trading volume of 14.5881 million HKD [1] - In December last year, JACOS announced a collaboration agreement with AstraZeneca for its self-developed Pan-KRAS inhibitor JAB-23E73 [1] - The company’s core pipeline, JAB-23E73, is expected to achieve a peak sales revenue of 1.2 billion RMB in the domestic market, and 1.9 billion USD in overseas markets, adjusted for risk [1] Group 2 - The KRAS G12C inhibitor, Goleirese, is set to be included in the national medical insurance catalog in January 2026, which is anticipated to drive rapid sales growth under the commercialization efforts of Elys [1]

Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase of over 6%, currently trading at 6.06 HKD with a transaction volume of 14.5881 million HKD, following the announcement of a collaboration with AstraZeneca on its proprietary Pan-KRAS inhibitor JAB-23E73 [1] Group 1: Company Developments - 加科思 announced a collaboration with AstraZeneca regarding its Pan-KRAS inhibitor JAB-23E73 in December last year [1] - The company’s core pipeline product, JAB-23E73, is projected to achieve a peak sales revenue of 1.2 billion RMB in the domestic market, adjusted for risk [1] - In the overseas market, the peak sales revenue for JAB-23E73 is expected to reach 1.9 billion USD, with an unadjusted figure of 7.2 billion USD [1] Group 2: Market Impact - The KRAS G12C inhibitor, 戈来雷塞, is set to be included in the national medical insurance directory starting January 2026, which is anticipated to drive rapid sales growth under the commercialization efforts of 艾力斯 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加科思藥業集團有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | 本月底法定/註 ...